Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Patanol Articles

Novartis wins in Apotex patent case; gout drug ACZ885 reduced risk of new attacks by up to 68% vs steroid

26 May 2011

Operating income up 21% at Kyowa Hakko

4 February 2008

Japan stock market week to November 5, 2007

12 November 2007

Alcon amends NDA for Patanase

15 October 2007

Kyowa Hakko's fiscal 1st-qtr sales rise 10.8%

6 August 2007

Japan stock market week to May 7, 2007

14 May 2007

Kyowa Hakko's fiscal 2006 profit falls 22%

7 May 2007

Kyowa's net income falls 47.5% to 3.9B yen

6 November 2006

Tokyo pharma stocks - week to july 12

19 July 2004

Tokyo pharma stocks - week to July 8

15 July 2002

Tokyo pharma stock market week to April 16

18 April 2001

Market News

30 October 1997

Japan stock market week to Nov 14

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS